The Kynurenine Metabolite 3-Hydroxykynurenine is Associated With Risk of Heart Failure in Patients With Predominantly Stable Coronary Artery Disease
International Journal of Tryptophan Research · 2026-08 · 19
DOI: 10.1177/11786469261479281 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Tryptophan Research, online erschienen am 18.08.2026. Verfasst von Anders Lund und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Haukeland University Hospital, Bergen, Norway. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helse Vest.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Inflammation and immune activation contribute to the development and progression of heart failure (HF). The kynurenine pathway, linking tryptophan metabolism to inflammation, oxidative stress, and cell death by way of its metabolites (kynurenines), has not been studied as a pathway associated with risk for incident HF.
Aims
To investigate whether kynurenine metabolites are associated with incident HF in patients with predominantly stable coronary artery disease.
Methods
Serum kynurenine metabolites were quantified in 3841 patients who underwent elective coronary angiography for evaluation of chest pain. Fasting was not routine. Patients with established HF at baseline were excluded. The hazard for incident HF was estimated using Cox regression, adjusted for age, gender, current smoking, diabetes, hypertension, previous myocardial infarction, body mass index, glomerular filtration rate, troponin T, left ventricular ejection fraction, and resting heart rate.
Results
During follow-up, 221 participants developed HF. Higher serum concentrations of 3-hydroxykynurenine (HK) were associated with increased HF risk (adjusted HR 1.31, 95% CI 1.07-1.46, P < .001).
Conclusion
Higher plasma HK was independently associated with incident HF in patients with predominantly stable coronary artery disease. These findings support a possible link between kynurenine pathway activity and future HF risk, but the underlying mechanisms and clinical implications remain to be established.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Sciences, University of Bergen, Norway.
- Voss Hospital, Haukeland University Hospital, Bergen, Norway.
- Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
- Bevital AS, Bergen, Norway.
- Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
ORCID-Profile: Lasse M Giil
Förderung
- Helse Vest
Zitieren
APA
Lund, A., Nordrehaug, J. E., Flo, K. C., Toresen, K. H., Alsing, C., McCann, A., Ueland, P. M., Nygård, O., & Giil, L. M. (2026). The Kynurenine Metabolite 3-Hydroxykynurenine is Associated With Risk of Heart Failure in Patients With Predominantly Stable Coronary Artery Disease. International Journal of Tryptophan Research, 19. https://doi.org/10.1177/11786469261479281
Vancouver
Lund A, Nordrehaug JE, Flo KC, Toresen KH, Alsing C, McCann A, et al. The Kynurenine Metabolite 3-Hydroxykynurenine is Associated With Risk of Heart Failure in Patients With Predominantly Stable Coronary Artery Disease. International Journal of Tryptophan Research. 2026;19. doi:10.1177/11786469261479281
BibTeX
@article{Lund2026,
author = {Lund, Anders and Nordrehaug, Jan Erik and Flo, Kjell-Christian and Toresen, Kyrre Hasås and Alsing, Christian and McCann, Adrian and Ueland, Per Magne and Nygård, Ottar and Giil, Lasse M},
title = {The Kynurenine Metabolite 3-Hydroxykynurenine is Associated With Risk of Heart Failure in Patients With Predominantly Stable Coronary Artery Disease},
journal = {International Journal of Tryptophan Research},
year = {2026},
volume = {19},
doi = {10.1177/11786469261479281}
}
EUVIMED